- Home
- KTRA
as 07-26-2024 4:00pm EST
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 13.9M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.08 - $5.00 | Next Earning Date: | 09-16-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kintara Therapeutics Inc. News
KTRA Breaking Stock News: Dive into KTRA Ticker-Specific Updates for Smart Investing
PR Newswire
19 days ago
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
PR Newswire
a month ago
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones
ACCESSWIRE
2 months ago
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
PR Newswire
2 months ago
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
Zacks
4 months ago
Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA
ACCESSWIRE
4 months ago
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
PR Newswire
4 months ago
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab
PR Newswire
5 months ago
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update
Compare KTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KTRA Kintara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.